Optimization of human immunodeficiency virus gag expression by newcastle disease virus vectors for the induction of potent immune responses.
One attractive strategy for the development of a human immunodeficiency virus (HIV) vaccine is the use of viral vectors with a proven safety profile and an absence of preexisting immunity in humans, such as Newcastle disease virus (NDV). Several NDV vaccine vectors have been generated, and their immunogenicities have been investigated with different animal models. However, a systematic study to evaluate the optimal insertion site of the foreign antigens into NDV that results in enhanced immune responses specific to the antigen has not yet been conducted. In this article, we describe the ability of NDV expressing HIV Gag to generate a Gag-specific immune response in mice. We also have determined the optimal insertion site into the NDV genome by generating recombinant NDV-HIVGag viruses in which HIV gag was located at different transcriptional positions throughout the NDV viral genome. All recombinant viruses were viable, grew to similar titers in embryonated chicken eggs, and expressed Gag in a stable manner. Our in vivo experiments revealed that higher HIV Gag protein expression positively correlates with an enhanced CD8(+) T-cell-mediated immune response and protective immunity against challenge with vaccinia virus expressing HIV Gag. We also inserted a codon-optimized version of HIV gag in the described best location, between the P and M genes. Virus expressing the codon-optimized version of HIV gag induced a higher expression of the protein and an enhanced immune response against HIV Gag in mice. These results indicate that strategies directed toward increasing antigen expression by NDV result in enhanced immunogenicity and vaccine efficacy.
Carnero
Elena
E
Department of Microbiology, Mount Sinai School of Medicine, New York, New York 10029, USA.
Li
Wenjing
W
Borderia
Antonio V
AV
Moltedo
Bruno
B
Moran
Thomas
T
García-Sastre
Adolfo
A
D016915:AIDS Vaccines / Q000235:genetics / Q000276:immunology*; D000818:Animals; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology*; D002642:Chick Embryo; D005260:Female; D015870:Gene Expression; D005822:Genetic Vectors; D051379:Mice; D008807:Mice, Inbred BALB C; D050296:Microbial Viability; D009522:Newcastle disease virus / Q000235:genetics* / Q000254:growth & development; D011995:Recombination, Genetic; D014615:Vaccinia / Q000517:prevention & control; D010948:Viral Plaque Assay; D014766:Viremia / Q000517:prevention & control; D054301:gag Gene Products, Human Immunodeficiency Virus / Q000096:biosynthesis* / Q000235:genetics
D016915:AIDS Vaccines; D054301:gag Gene Products, Human Immunodeficiency Virus